Old names:
Owner | Filings | Transaction Date | Type of Owner |
---|---|---|---|
GIBSON TERRY | 0001264193 | Oct-29-2010 | officer: CEO and CFO, other: See Explanation of Responses |
LICHTENSTEIN WARREN G | 0001005784 | Oct-22-2010 | 10 percent owner |
HOWARD JACK L | 0001144269 | Oct-22-2010 | director, other: See Explanation of Responses |
EMH Howard LLC | 0001443099 | Oct-22-2010 | other: See Explanation of Responses |
Kong Kenneth | 0001504324 | Oct-22-2010 | director, other: See Explanation of Responses |
Steel Partners, Ltd. | 0001504325 | Oct-22-2010 | 10 percent owner |
FORDYCE JAMES W | 0001094878 | Jul-31-2009 | director |
Palleiko Benjamin L | 0001366244 | Jul-15-2009 | officer: SVP & Chief Financial Officer |
Dunne Chris T | 0001461991 | Apr-01-2009 | officer: Principal Accounting Officer |
Donahue Stephen R | 0001462323 | Mar-12-2009 | officer: Senior Vice President |
URDAL DAVID | 0001242879 | Apr-09-2007 | director |
Gabrielson Mark J | 0001396131 | Apr-09-2007 | director |
MILLER LLOYD I III | 0000949119 | Oct-20-2006 | 10 percent owner |
Tiffany Larry M | 0001368284 | Jun-27-2006 | officer: SVP & Interim GM Gemonics |
Tartaglia Louis A | 0001365332 | Jun-01-2006 | officer: SVP & GM Drug Repositioning |
Brinkerhoff Van Wyck | 0001319765 | Mar-06-2005 | officer: Sr. VP & General Manager |
Barger Dennis | 0001316290 | Jan-26-2005 | officer: VP Global Business Development |
Douglas Frank L | 0001310452 | Nov-24-2004 | director |
ROSSI DENNIS | 0001223360 | Sep-17-2004 | officer: GM Gene Logic Genomics |
Smith-Farrell Joanne | 0001304048 | Sep-17-2004 | officer: VP Corp Development & Strategy |
DIMMLER CHARLES L III | 0001032354 | Jun-03-2004 | director |
DOLGINOW Y DOUGLAS MD | 0001241140 | Jun-03-2004 | officer: Sr. VP Pharmacogenomics |
BLAKE JULES PHD | 0001241144 | Jun-03-2004 | director |
GORRY G ANTHONY PHD | 0001241145 | Jun-03-2004 | director |
THOMPSON J STARK PHD | 0001241146 | Jun-03-2004 | director |
GESSLER MARK D | 0001241136 | Jul-31-2003 | director, officer: CEO and President |
ROHRER PHILIP L JR | 0001241139 | Jul-31-2003 | officer: Chief Financial Officer |
STAPLES F DUDLEY JR | 0001241143 | Jul-31-2003 | officer: Senior VP, Secretary |
PROULX ROBERT | 0001252765 | Jul-08-2003 | officer: Senior Vice President |
BRENNAN MICHAEL J | 0001241260 | Jun-13-2003 | director |
Coming soon!
Coming soon!
Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by ORE PHARMACEUTICAL HOLDINGS INC.
Filings | Format | Description | Filed/Effective | File/Film Number |
---|---|---|---|---|
SC 13G/A | Document | Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0001037389-11-000070 (34 Act) Size: 16 KB |
Feb-11-2011 | 11596680 |
3 | Document | Initial statement of beneficial ownership of securities Acc-no: 0000921895-10-001633 ( Act) Size: 4 KB |
Nov-05-2010 | |
3 | Document | Initial statement of beneficial ownership of securities Acc-no: 0000921895-10-001611 ( Act) Size: 6 KB |
Nov-01-2010 | |
3 | Document | Initial statement of beneficial ownership of securities Acc-no: 0000921895-10-001610 ( Act) Size: 4 KB |
Nov-01-2010 | |
SC 13D | Document | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities Acc-no: 0000921895-10-001608 (34 Act) Size: 419 KB |
Nov-01-2010 | 101155727 |
4 | Document | Statement of changes in beneficial ownership of securities Acc-no: 0000921895-10-001596 ( Act) Size: 8 KB |
Oct-29-2010 | |
3 | Document | Initial statement of beneficial ownership of securities Acc-no: 0000921895-10-001595 ( Act) Size: 6 KB |
Oct-29-2010 | |
15-12G | Document | Notice of termination of registration of a class of securities under Section 12(g) Acc-no: 0001157523-10-005617 (34 Act) Size: 3 KB |
Sep-24-2010 | 101089042 |
CT ORDER | Document | Acc-no: 9999999997-10-018086 (34 Act) Size: 19 KB | Sep-23-2010 | 101087045 |
10-Q | Document | Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0001157523-10-004995 (34 Act) Size: 591 KB |
Aug-11-2010 | 101008124 |
8-K | Document | Current report filing Acc-no: 0001157523-10-004200 (34 Act) Size: 23 KB |
Jul-22-2010 | 10965021 |
10-Q | Document | Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0001157523-10-003059 (34 Act) Size: 353 KB |
May-11-2010 | 10820980 |
10-K/A | Document | Amendment to Annual report pursuant to section 13 and 15(d) Acc-no: 0001157523-10-002542 (34 Act) Size: 377 KB |
Apr-29-2010 | 10782363 |
8-K | Document | Current report filing Acc-no: 0001157523-10-002109 (34 Act) Size: 23 KB |
Apr-19-2010 | 10757468 |
25-NSE | Document | Acc-no: 0001354457-10-000082 (34 Act) Size: 4 KB | Apr-05-2010 | |
10-K | Document | Annual report pursuant to section 13 and 15(d) Acc-no: 0001157523-10-001855 (34 Act) Size: 1101 KB |
Mar-31-2010 | 10720533 |
8-K | Document | Current report filing Acc-no: 0001157523-10-001660 (34 Act) Size: 15 KB |
Mar-22-2010 | 10696692 |
8-K | Document | Current report filing Acc-no: 0001157523-10-000888 (34 Act) Size: 5 KB |
Feb-12-2010 | 10600651 |
SC 13G/A | Document | Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0001037389-10-000248 (34 Act) Size: 13 KB |
Feb-12-2010 | 10594803 |
SC 13G/A | Document | Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0000354204-10-001308 (34 Act) Size: 51 KB |
Feb-08-2010 | 10579712 |
Recent 20 filings. View all ORE PHARMACEUTICAL HOLDINGS INC. filings
young lad who new his job ansered questions and new what was best for me.
It's being easier working on the website. And I recommend, it's a great website
Huge help thank you for your help .. y'all make it so much easier
Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.
© 2022 CompaniesBIO.Com. All rights reserved. Operated by